The global oncology radiopharmaceuticals market is one of the most lucrative segments in the pharmaceutical industry. Oncology radiopharmaceuticals find wide applications in diagnosis and treatment of various cancers including lung cancer, breast cancer, prostate cancer, lymphoma, leukemia, gastrointestinal cancer, neuroendocrine tumors and others. They help in visualization and localization of tumors in the body with the help of medical imaging technologies such as SPECT and PET scans. Some key advantages of utilizing radiopharmaceuticals in oncology include high sensitivity and specificity for detecting cancer, ability to track tumor response to therapies non-invasively and guide radiation treatment planning.
The global oncology radiopharmaceuticals market is estimated to be valued at US$ 8468.36 Mn in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period 2024 to 2030.
Increasing prevalence of cancer attributed to aging population and changing lifestyle habits is a major factor driving the demand for advanced cancer diagnostic and treatment approaches. According to WHO, cancer burden has risen to 19.3 Mn new cases and 10 Mn cancer deaths in 2020. Continued approval and launches of new radioisotopes with improved drug characteristics coupled with expanding indications are further fueling the market growth.
Key Takeaways
Key players operating in The Oncology Radiopharmaceuticals are Accord Healthcare Inc., Viatris Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., Torrent Pharmaceuticals Ltd., Dr Reddy's Laboratories Ltd., Unichem Laboratories Ltd., Apotex Inc. and Intas Pharmaceuticals Ltd.
The key opportunities in the oncology radiopharmaceuticals market include novel radioisotope based targeted drugs in pipeline, growing trend of personalized medicine and investments in theranostic radiotracers. Major pharma players are engaged in R&D of alpha and beta emitting isotopes along with antibodies and peptides for optimal delivery to cancer sites and assessment of treatment response.
North America dominates the global market currently owing to advanced healthcare systems and widespread adoption of radiotracers in cancer management. However, Asia Pacific region is anticipated to offer most lucrative growth prospects during the forecast period supported by rising healthcare expenditure, large cancer patient pool and focus of global pharma companies to tap emerging Asia Pacific countries.
Market Drivers
- Increasing incidence of cancer worldwide promoting early detection and disease monitoring
- Expanding applications of PET and SPECT imaging in oncology clinical practices
- Continuous pipeline of innovative targeted radiopharmaceuticals entering the market
Market Restraints
- High infrastructure and capital investments required for radioisotope production and imaging facilities
- Stringent regulatory pathways and reimbursement challenges for approval of new radioisotopes
- Short half-life of radioisotopes requiring on-site generation or distribution networks
Segment Analysis
The oncology radiopharmaceuticals market comprises of various segments such as diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. Diagnostic radiopharmaceuticals dominate the market currently holding around 65% share as diagnosis of cancer is the first step for treatment. These diagnostic radiotracers help detect tumours at an early stage and determine the cancer type which helps in deciding appropriate treatment options. The use of diagnostic radiotracers for PET scans is growing at a faster rate due to advantages like high sensitivity, specificity, and ability to provide functional and molecular information.
Global Analysis
North America dominates the oncology radiopharmaceuticals market currently holding over 40% share. Presence of well-established healthcare infrastructure, favorable reimbursement policies, and higher healthcare spending are driving market growth in the region. Asia Pacific is expected to witness the highest growth during the forecast period owing to growing incidences of cancer, increasing awareness about diagnostic imaging, and improving healthcare infrastructure in emerging economies like China and India. The rising number of hospitals, diagnostic centers adopting nuclear medicine techniques for diagnosis and treatment of cancer also supports regional market growth.
Get more insights on Oncology Radiopharmaceuticals Market
Comments
0 comment